Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin

Diabetes, Obesity and Metabolism

Volumn 16, Issue 7, 2014, Pages 645-650

  Grandy, S ^a   Hashemi, M ^b   Langkilde, A M ^b   Parikh, S ^a   Sjostrom C D ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Antidiabetic drug; Clinical trial; Diabetes mellitus; Human adipose tissue; Randomized trial; SGLT2 inhibitor

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; METFORMIN; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES WEIGHT QUESTIONNAIRE 9; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; FEMALE; FISHER EXACT TEST; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SELF ESTEEM; TREATMENT DURATION; URINARY EXCRETION; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; HEALTH STATUS; MIDDLE AGED; QUESTIONNAIRE; RISK ASSESSMENT; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEALTH STATUS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RISK ASSESSMENT; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84903179652     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12263     Document Type: Article

References (15)

1. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938.
2. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
3. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
4. Bolinder J, Ljunggren Ö, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemia control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
5. Ljunggren Ö, Bolinder J, Johansson L et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012; 14: 990-999.
6. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. A position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
7. International Diabetes Federation. Diabetes Atlas. 2012. Available from URL: http://www.diabetesatlas.org. Accessed 18 April 2013.
8. Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 882-892.
9. Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomized placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord 2004; 28: 600-605.
10. Grandy S, Fox KM, Bazata DD. Association of self-reported weight change and quality of life, and exercise and weight management behaviors among adults with type 2 diabetes mellitus: The SHIELD study. Cardiol Res Pract 2012; 2012: 892564.
11. Grandy S, Fox KM, Bazata DD. for the SHIELD Study Group. Health-related quality of life association with weight change in type 2 diabetes mellitus: perception vs. reality. Int J Clin Pract 2013; 67: 455-461.
12. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35: 731-737.
13. Chisholm-Burns MA, Spivey CA. The 'cost' of medication nonadherence: consequences we cannot afford to accept. J Am Pharm Assoc 2012; 52: 823-826.
14. Egede LE, Gebregziabher M, Dismuke CE et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care 2012; 35: 2533-2539.
15. Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood) 2012; 31: 1836-1846.